ADMA Biologics (ADMA) reported Q1 earnings late Wednesday of $0.11 per diluted share, up from $0.08 a year earlier.
Three analysts polled by FactSet expected $0.15.
Revenue in the three months ended March 31 rose to $114.8 million from $81.9 million a year earlier. Three analysts surveyed by FactSet expected $116.4 million.
The company raised 2025 revenue guidance to over $500 million from over $490 million and boosted the 2026 forecast to over $625 million from $605 million.
Three analysts expect $496.1 million this year and $629.7 million in 2026.
The board authorized a stock repurchase program of up to $500 million
The company's shares fell 4.7% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.